Abstract
Purpose: Data about the effect of multifetal pregnancy reduction on midtrimester maternal serum levels of α-feto-protein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol (uE 3 ) are scarce and contradictory. Differing gestational ages at fetal reduction, transvaginal versus transabdominal needle insertion, and injection of different feticidal agents compound the analysis of published data.
Methods: We examined clinical and laboratory data about 27 high-order gestations that were reduced to twins in the first trimester. Fetal reductions were performed transabdominally at 11.41 ± 1.15 weeks' gestation by fetal intrathoracic injection of KCl, and maternal blood sampling was performed at 16.48 ± 1.05 weeks. “Pseudo-risks” for singleton pregnancies were calculated by correcting serum analyte levels for twins.
Results: Twenty-four (88.9%) of 27 patients had maternal serum AFP levels above 2.0 MoM (mean, 4.60 ± 3.48 MoM; range, 1.49–14.85 MoM), however, none of the newborns had structural anomalies. AFP serum levels did not correlate with the number of reduced fetuses or with adverse obstetric outcome. The mean hCG levels were 1.22 ± 0.49 MoM (range, 0.14–2.47), and the mean uE 3 levels were 1.15± 0.31 MoM (range, 0.56–1.84). Based on maternal age alone, seven patients (25.9%) would have been offered amniocentesis for a term Down syndrome risk greater than 1:384, whereas combined risk calculations with hCG and uE 3 levels resulted in 1 (3.7%) screen-positive case (P < 0.01).
Conclusions: Midtrimester maternal serum AFP levels after multifetal reduction should not be used for screening purposes, whereas incorporation of hCG and uE 3 levels might reduce risk estimates for Down syndrome and the need for invasive testing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Schenker JG, Yarkoni S, Granat M: Multiple pregnancies following induction of ovulation. Fertil Steril 1981;35:105–123
Luke B, Keith LG: The contribution of singletons, twins and triplets to low birth weight, infant mortality and handicap in the United States. J Reprod Med 1992;37:661–666
Evans MI, Dommergues M, Timor-Tritsch I, Zador IE, Wapner RJ, Lynch L, Dumez Y, Goldberg JD, Nicolaides KH, Johnson MP, Golbus MS, Boulot P, Aknin AJ, Monteagudo A, Berkowitz RL: Transabdominal versus transcervical and transvaginal multifetal pregnancy reduction: international collaborative experience of more than one thousand cases. Am J Obstet Gynecol 1994;170:902–909
Bernabei VM, Krantz DA, Macri JN, Larsen JW. Enhanced twin pregnancy detection with open neural tube defect and Down syndrome screening protocol using free-beta hCG and AFP. Prenat Diagn 1995;15:1131–1134
Neveux LM, Palomaki GE, Knight GJ, Haddow JE: Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 1996;16:29–34
Grau P, Robinson L, Tabsh K, Crandal BF: Elevated maternal serum alpha-fetoprotein and amniotic fluid alpha-fetoprotein after multifetal pregnancy reduction. Obstet Gynecol 1990;76:1042–1045
Lynch L, Berchowitz RL: Maternal serum α-fetoprotein and coagulation profiles after multifetal pregnancy reduction. Am J Obstet Gynecol 1993;169:987–990
Shulman LP, Phillips OP, Cervetti TA: Maternal serum analyte levels after first-trimester multifetal pregnancy reduction. Am J Obstet Gynecol 1996;174:1072–1074
Groutz A, Amit A, Yaron Y, Yovel I, Wolman I, Legum C, Lessing JB: Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction. Prenat Diagn 1996;16:723–727
Frishman GN, Caick JA, Hogan JW, Hackett RJ, Kellner LH, Saller DN: Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies. Obstet Gynecol 1997;90:98–101
Berkowitz RL, Lynch L, Chitkara U, Wilkins IA, Mehalek KE, Alvarez E: Selective reduction of multifetal pregnancies in the first trimester. Lancet 1988;318:1043–1047
Wald NJ, Cuckle HS, Hu T, George L: Maternal serum unconjugated oestriol and human chorionic gonadotropin levels in twin pregnancies: implications for screening for Down's syndrome. Br J Obstet Gynecol 1991;98:905–908
Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M: A United States national reference for fetal growth. Obstet Gynecol 1996;87:163–168
Abbas A, Johnson M, Bersinger N, Nicolaides KH: Maternal alpha-fetoprotein levels in multiple pregnancies. Br J Obstet Gynecol 1994;101:156–158
Shulman LP, Phillips OP: Re: Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction. Prenat Diagn 1997;17:488–490
Kallen B, Cocchi G, Knudsen LB, Castilla EE, Robert E, Kjersti Daltveit A, Lancaster PL, Mastroiacovo P: International study of sex ratio and twinning of neural tube defects. Teratology 1994;50:322–331
Johnson JM, Harman CR, Evans AJ, MacDonald K, Manning FA: Maternal serum α-fetoprotein in twin pregnancy. Am J Obstet Gynecol 1990;162:1020–1025
Evans MI, Littmann L, StLuis L, LeBlanc L, Addis J, Johnson MP, Moghissi KS: Evolving patterns of iatrogenic multifetal pregnancy generation: Implications for aggressiveness of infertility treatments. Am J Obstet Gynecol 1995;172:1750–1755
Kiely JK: What is the population-based risk of preterm birth among twins and other multiples. Clin Obstet Gynecol 1998;41:3–11
Wapner RJ: Genetic diagnosis in multiple pregnancies. Semin Perinatol 1995;19:351–362
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rotmensch, S., Celentano, C., Shalev, J. et al. Midtrimester Maternal Serum Screening After Multifetal Pregnancy Reduction in Pregnancies Conceived by In Vitro Fertilization. J Assist Reprod Genet 16, 8–12 (1999). https://doi.org/10.1023/A:1022585326896
Issue Date:
DOI: https://doi.org/10.1023/A:1022585326896